Agios Pharmaceuticals, Inc.
- Open
- 33.60
- Day high
- 34.34
- Day low
- 33.21
- Prev close
- 33.68
- Volume
- 44K
- Mkt cap
- $2.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.0
- P/S
- 20.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.1M over the last 3 months (0 open-market buys, 2 sales)
- 🏛Institutions accumulating (13F)
Agios Pharmaceuticals, Inc. (AGIO) is a Healthcare company listed on NASDAQ. The stock is down 15% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 2 sales (SEC Form 4).
Agios Pharmaceuticals, Inc. (AGIO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AGIO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $-1.65 | $-1.69 | -2.4% | $45M | +70.9% |
| Apr 29, 2026 | $-1.81 | $-1.69 | +6.6% | $21M | +56.2% |
| Feb 12, 2026 | $-1.97 | $-1.86 | +5.6% | $20M | +26.7% |
| Oct 30, 2025 | $-1.93 | $-1.78 | +7.8% | $13M | +10.1% |
| Jul 31, 2025 | $-1.74 | $-1.93 | -10.9% | $12M | +20.8% |
| May 1, 2025 | $-1.80 | $-1.55 | +13.9% | $9M | -13.1% |
| Feb 13, 2025 | $-1.69 | $-1.74 | -3.0% | $11M | +14.6% |
| Oct 31, 2024 | $16.69 | $4.20 | -74.8% | $9M | -4.4% |
| Aug 1, 2024 | $-1.58 | $-1.69 | -7.0% | $9M | -8.0% |
| May 2, 2024 | $-1.64 | $-1.45 | +11.6% | $8M | -16.4% |
| Feb 15, 2024 | $-1.64 | $-1.72 | -4.9% | $7M | -11.7% |
| Nov 2, 2023 | $-1.69 | $-1.64 | +3.0% | $7M | -1.7% |
AGIO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 6, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Sell | 30,000 | $30.48 |
| Jul 10, 2026 | Backstrom Jay T.director | Option | 1,447 | — |
| Jul 10, 2026 | Backstrom Jay T.director | Grant | 1,447 | — |
| Jul 2, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Sell | 4,007 | $37.56 |
| Jul 2, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Option | 8,375 | — |
| Jun 23, 2026 | Scadden Daviddirector | Option | 2,816 | — |
| Jun 23, 2026 | Smith Cynthiadirector | Option | 2,816 | — |
| Jun 23, 2026 | Viswanadhan Krishnanofficer: Chief Strategy and Operations | Grant | 3,000 | — |
| Jun 23, 2026 | Foster-Cheek Kaye Idirector | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | FOUSE JACQUALYN Adirector | Grant | 2,927 | — |
| Jun 23, 2026 | Scadden Daviddirector | Grant | 2,927 | — |
| Jun 23, 2026 | Jones Ceciliaofficer: Chief Financial Officer | Option | 3,000 | — |
| Jun 23, 2026 | Foster-Cheek Kaye Idirector | Option | 2,816 | — |
| Jun 23, 2026 | Milanova Tsvetaofficer: Chief Commercial Officer | Grant | 3,000 | — |
| Jun 23, 2026 | Goff Briandirector, officer: Chief Executive Officer | Grant | 39,000 | — |
Source: AGIO SEC Form 4 filings, latest Aug 6, 2026. For informational purposes only — not investment advice.
See the full AGIO insider & 13F page →Agios Pharmaceuticals, Inc. company profile
Overview
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company founded in 2007 and headquartered in Cambridge, Massachusetts. The company went public in July 2013 and specializes in discovering and developing medicines targeting cellular metabolism and adjacent areas of biology. Agios has successfully commercialized its first product, PYRUKYND (mitapivat), for treating rare blood disorders, and maintains a robust pipeline of investigational therapies for various hemolytic anemias and other metabolic conditions.
Business
Agios operates in the biotechnology sector, focusing specifically on cellular metabolism - the fundamental processes by which cells generate and use energy. The company's core expertise lies in developing treatments for rare blood disorders called hemolytic anemias, conditions where red blood cells are destroyed faster than they can be produced, leading to fatigue, organ damage, and other serious complications. The company's flagship commercial product is PYRUKYND (mitapivat), an oral medication that works as a pyruvate kinase activator. Pyruvate kinase is a crucial enzyme in the glycolytic pathway that helps red blood cells produce energy. In patients with pyruvate kinase deficiency, this enzyme doesn't function properly, causing red blood cells to break down prematurely. PYRUKYND activates both normal and mutant forms of this enzyme, helping red blood cells survive longer and reducing anemia symptoms. Beyond its approved indication for pyruvate kinase deficiency, Agios is developing PYRUKYND for multiple other hemolytic anemias including thalassemia (a genetic disorder affecting hemoglobin production) and sickle cell disease (where red blood cells become misshapen and break down). The company is also developing tebapivat (AG-946), another pyruvate kinase activator, and AG-236, a novel siRNA therapy targeting a different metabolic pathway. Currently, PYRUKYND for pyruvate kinase deficiency represents virtually 100% of the company's product revenue, generating approximately $37 million in 2024. However, the potential expansion into thalassemia and sickle cell disease markets could significantly diversify and expand the revenue base, with management targeting potential launches in 2025 and 2026 respectively.
Revenue model
Agios generates revenue primarily through direct product sales of PYRUKYND to specialty pharmacies and healthcare providers. The company targets a highly specialized customer base of hematologists and hematology-oncology practices that treat patients with rare blood disorders. Currently, approximately 150 such practices in the United States treat the majority of patients with these conditions. The business model is characteristic of rare disease pharmaceuticals, featuring high per-patient pricing to offset the small patient populations. PYRUKYND's current market for pyruvate kinase deficiency includes only a few hundred diagnosed patients globally, necessitating premium pricing to achieve commercial viability. The company also receives milestone payments from partnership agreements, most notably the $1.1 billion received in 2024 from the FDA approval of vorasidenib, a cancer drug developed through a partnership. Several factors could significantly impact Agios's margins and revenue potential. Positive factors include successful regulatory approvals for larger patient populations (thalassemia affects approximately 6,000 diagnosed adults in the US, while sickle cell disease affects around 100,000 patients), which would provide substantial revenue expansion opportunities. The oral administration and favorable safety profile of PYRUKYND could drive higher adoption rates compared to existing treatments that often require frequent medical interventions. Challenging factors include the inherent difficulties in rare disease markets, such as slow patient identification and diagnosis, physician education requirements, and complex insurance approval processes. Competition from other companies developing treatments for these same conditions could pressure pricing and market share. Additionally, the company faces significant regulatory risks, as evidenced by the recent withdrawal of a competing sickle cell disease treatment due to safety concerns, which has heightened regulatory scrutiny for the entire therapeutic area. The company's substantial R&D expenses (approximately $290 million annually) and ongoing clinical trial costs create significant cash burn, requiring successful commercialization to achieve profitability. Management targets cash flow positivity by 2026, contingent on successful product launches in expanded indications.
Competitive moat
Agios possesses a moderate but defensible moat built primarily around its scientific expertise in cellular metabolism and first-mover advantage in pyruvate kinase activation. The company's deep understanding of metabolic pathways and proven ability to develop effective pyruvate kinase activators creates meaningful barriers to entry, as this requires specialized knowledge and years of research and development. The company's regulatory approvals and clinical data represent significant competitive advantages. PYRUKYND's FDA approval for pyruvate kinase deficiency establishes Agios as the first and currently only approved treatment for this condition. The extensive clinical trial data across multiple hemolytic anemias provides a substantial head start over potential competitors who would need to conduct their own lengthy and expensive studies. However, the moat faces several vulnerabilities. The patent protection for PYRUKYND and related compounds will eventually expire, potentially allowing generic competition. More immediately, other biotechnology companies are developing alternative approaches to treating the same conditions, including gene therapies and other small molecule treatments. The recent regulatory challenges in sickle cell disease treatments demonstrate how quickly competitive dynamics can shift in rare disease markets. The company's commercial infrastructure and relationships with key hematology practices provide some defensive value, but this advantage is not insurmountable for well-funded competitors. Additionally, the relatively small patient populations in rare diseases mean that even modest competition can significantly impact market share and pricing power. Overall, while Agios has built meaningful competitive advantages through its scientific expertise and regulatory achievements, the moat is not exceptionally wide and requires continued innovation and successful execution to maintain its defensive characteristics.
Risks & safety
Agios demonstrates a strong margin of safety from a financial solvency perspective, though faces execution risks typical of clinical-stage biotechnology companies. • Liquidity position: Exceptionally strong with $1.5 billion in cash and marketable securities as of Q4 2024, providing substantial runway for operations • Debt levels: Minimal debt with debt-to-equity ratio of only 0.037, indicating very low financial leverage • Cash burn: Operating cash flow negative at approximately $390 million annually, but current cash position provides runway through 2027-2028 at current burn rates • Current ratio: Excellent at 11.9x, indicating strong ability to meet short-term obligations • Valuation metrics: Mixed signals with P/E ratio of 2.8x based on 2024 net income (inflated by one-time milestone payment), but underlying operations remain unprofitable • Enterprise value: Trading at negative EV/EBITDA due to substantial cash position exceeding market capitalization • Graham metrics: Strong net-net working capital position suggests potential downside protection • Other considerations: Primary risks center on clinical trial execution, regulatory approval outcomes, and commercial launch success rather than financial distress. The company's substantial cash position provides significant buffer against operational setbacks.
Recent development
Over the past few years, Agios has executed a strategic transformation from a research-focused biotechnology company to a commercial-stage rare disease specialist. The most significant development was the successful launch of PYRUKYND for pyruvate kinase deficiency in 2022, marking the company's transition to generating product revenues after years of operating as a pure research and development entity. The company has systematically expanded its clinical development program to address larger patient populations beyond the initial pyruvate kinase deficiency indication. Key clinical milestones include positive Phase 3 results in thalassemia (ENERGIZE and ENERGIZE-T studies), completion of enrollment in the Phase 3 sickle cell disease study (RISE UP), and successful pediatric studies. These achievements position Agios for potential regulatory submissions and product launches in significantly larger markets, with thalassemia targeted for 2025 and sickle cell disease for 2026. Agios has also diversified its pipeline beyond PYRUKYND, initiating development of tebapivat (AG-946) as a next-generation pyruvate kinase activator and AG-236 as a novel siRNA therapy. The company received FDA orphan drug designation for tebapivat in myelodysplastic syndromes, expanding into adjacent therapeutic areas beyond hemolytic anemias. The company's financial position was dramatically strengthened by the $1.1 billion milestone payment received in 2024 following FDA approval of vorasidenib, a cancer treatment developed through a partnership. This windfall provides substantial resources for clinical development and commercial expansion while reducing dependence on external financing. Recent strategic moves include building commercial capabilities for the anticipated thalassemia launch, expanding the sales team to approximately 40 professionals, and establishing international partnerships such as the distribution agreement with NewBridge Pharmaceuticals for the Gulf Cooperation Council region. The company has also engaged in disciplined capital allocation discussions, balancing pipeline advancement with potential business development opportunities.
AGIO company profile · for informational purposes only — not investment advice.
Track AGIO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free